anagrelide (SAR001) / Sartar Therap - LARVOL DELTA

Pharmacokinetic profile and in vivo anticancer efficacy of anagrelide administered subcutaneously in rodents. (PubMed, Drug Deliv) - "The SC formulation also significantly reduced tumor volumes and demonstrated dose-dependent histological responses, nearly eradicating tumor tissue in 11 days with the highest dose. These findings suggest that the SC slow-release formulation maintains stable drug concentrations during treatment, potentially improving therapeutic efficacy at the target site."

Journal • PK/PD data • Preclinical • Essential Thrombocythemia • Gastrointestinal Disorder • Hematological Disorders • Myeloproliferative Neoplasm • Oncology • Sarcoma • Targeted Protein Degradation • Thrombocytosis • PDE3A

The SURPASS-ET study: evaluating novel treatment approaches in ET (YouTube) - "Srdan Verstovsek, MD, PhD...shares some insights into current treatment approaches in essential thrombocythemia (ET), and further discusses the main aims of the SURPASS-ET trial (NCT04285086), which is comparing the use of ropeginterferon alfa-2b versus anagrelide in patients with ET. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX."

Interview • Video